MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
sale of common stock...
$11,964,056
Proceeds from stock
option exercises
$6,986
Cash provided by
financing activities
$11,971,042
Net decrease in cash
and cash...
-$190,234
Canceled cashflow
$11,971,042
Maturities of marketable
investment securities
$5,300,000
License and royalties
receivable
-$1,025,993
Accounts payable
$590,906
Prepaid and other
current assets
-$502,545
Stock-based compensation
expense
$65,398
Depreciation expense
$14,814
Net cash used in
investing activities
-$9,904,139
Canceled cashflow
$5,300,000
Cash used in
operating activities
-$2,257,137
Canceled cashflow
$2,199,656
Purchases of marketable
investment securities
$15,204,139
Net loss
attributable to common...
-$3,671,894
Accrued expenses
-$591,259
Accrued interest income
$97,222
Amortization of discounts on
marketable investment...
$96,418
Back
Back
Cash Flow
source: myfinsight.com
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)